Table 1:
Identified agents’ current clinical indications, human pharmacokinetic properties (46–50) and estimated IC50 for inhibiting viral entry into Caco-2 cells.
| Drug | Disease | Regulatory Status | Dose | Route (frequency) | Cmax | In vitro IC50 (viral entry) | Reference |
|---|---|---|---|---|---|---|---|
| Homoharringto nine (Omacetaxine) | Chronic myeloid leukemia (CML) | FDA approved | 1.25 mg/m2 | SC (BID) | 55nM | ~30nM | [32] |
| Halofuginone | scleroderma | Phase 1/2 | 3.5mg/day | Oral | 7nM | ~30nM | [33] |
| Verteporfin | photosensitizer for photodynamic therapy | FDA approved | 0.3mg/kg | IV (within 45min) | 1.92μM | ~10μM | FDA |
| Cilnidipine | Hypertension | FDA approved | 10mg | Oral (QD) | 18.1nM | ~3μM | [34] |
| Dasatinib | chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) | FDA approved | 140mg | Oral (QD) | 0.307μM | >10μM | [35] |
| Venetoclax | chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | FDA approved | 400mg | Oral (QD) | 1.27μM | >10μM | [36] |